Proceedings of the 3rd Borobudur International Symposium on Humanities and Social Science 2021 (BIS-HSS 2021)

<Previous Article In Volume
Next Article In Volume>

Description of Antiviral Usage in Covid-19 Patients at One of COVID-19 Referral Hospital in Semarang City

Authors
Arik Dian Eka Pratiwi1, *, Dhimas Adhityasmara1, Erna Prasetya Ningrum1
1Department of Pharmacology and Clinical Pharmacy, Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang, 50192, Indonesia
*Corresponding author. Email: arikdianekapratiwi@stifar.ac.id
Corresponding Author
Arik Dian Eka Pratiwi
Available Online 29 December 2022.
DOI
10.2991/978-2-494069-49-7_48How to use a DOI?
Keywords
Antiviral; Favipiravir; Remdesivir; COVID-19 Medication
Abstract

COVID-19 is a pandemic that is causing increasing health burdens almost all over the world, and until the outbreak of the virus spreads, no effective therapy has been found to deal with the infection. As a result, effective antiviral therapy is needed to inhibit the spread of viral transmission. Several therapeutic drugs have been explored for COVID-19 therapy. Several therapeutic drugs have been explored for COVID-19 therapy. The goal of this study was to identified description of antiviral usage in medication of COVID-19 patients. This study was an observational study that retrospectively used medical records and drug usage records of 105 patients diagnosed as positive for COVID-19 and receiving antiviral medication during the June to December 2020 period. The results showed that the most widely used antiviral was favipiravir (34.30%) in a single administration, while the most commonly used combination was Favipiravir and Remdesivir (11.00%). For each patient, the clinical condition, dose, and duration of medication were adjusted. This research was very useful in obtaining information for pharmacists, especially those working in health services, especially in hospitals, in monitoring therapy and the effectiveness of antiviral usage so that they could help improve the patient’s condition.

Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 3rd Borobudur International Symposium on Humanities and Social Science 2021 (BIS-HSS 2021)
Series
Advances in Social Science, Education and Humanities Research
Publication Date
29 December 2022
ISBN
10.2991/978-2-494069-49-7_48
ISSN
2352-5398
DOI
10.2991/978-2-494069-49-7_48How to use a DOI?
Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Arik Dian Eka Pratiwi
AU  - Dhimas Adhityasmara
AU  - Erna Prasetya Ningrum
PY  - 2022
DA  - 2022/12/29
TI  - Description of Antiviral Usage in Covid-19 Patients at One of COVID-19 Referral Hospital in Semarang City
BT  - Proceedings of the 3rd Borobudur International Symposium on Humanities and Social Science 2021 (BIS-HSS 2021)
PB  - Atlantis Press
SP  - 290
EP  - 294
SN  - 2352-5398
UR  - https://doi.org/10.2991/978-2-494069-49-7_48
DO  - 10.2991/978-2-494069-49-7_48
ID  - Pratiwi2022
ER  -